Comparative Pharmacology
Head-to-head clinical analysis: CURRETAB versus CYCRIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CURRETAB versus CYCRIN.
CURRETAB vs CYCRIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progesterone receptor agonist; induces secretory changes in endometrium, inhibits pituitary gonadotropin secretion, and has anti-estrogenic effects.
Medroxyprogesterone acetate is a progestin that inhibits gonadotropin secretion, suppressing ovulation and inducing a withdrawal bleeding in an estrogen-primed endometrium. It exerts its effects via binding to progesterone receptors, leading to endometrial transformation and inhibition of endometrial proliferation.
5 mg orally once daily for 10 consecutive days per cycle, beginning on day 16 of the menstrual cycle.
2.5 mg to 10 mg orally once daily for 5 to 10 days per cycle.
None Documented
None Documented
Terminal elimination half-life of medroxyprogesterone acetate (MPA) is approximately 12-17 hours (mean ~14 h) for oral administration; with intramuscular depot, half-life extends to ~6-7 weeks due to slow absorption from injection site
Terminal elimination half-life ranges from 12 to 24 hours, supporting once-daily dosing for continuous hormone replacement.
Primarily renal (60-70% as metabolites, <10% unchanged); biliary/fecal (20-30%)
Primarily renal (50-60% as sulfate and glucuronide conjugates), with approximately 30% fecal elimination.
Category C
Category C
Progestin
Progestin